Success Metrics

Active Trials
7(78%)

Phase Distribution

Ph early_phase_1
1
11%
Ph phase_2
2
22%
Ph phase_1
6
67%

Phase Distribution

7

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
6(66.7%)
Phase 2Efficacy & side effects
2(22.2%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

9

all time

Status Distribution
Active(7)
Other(2)

Detailed Status

Recruiting6
Active, not recruiting1
Suspended1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
7
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (11.1%)
Phase 16 (66.7%)
Phase 22 (22.2%)

Trials by Status

active_not_recruiting111%
suspended111%
recruiting667%
unknown111%

Recent Activity

7 active trials
Showing 5 of 9
active_not_recruitingphase_1

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

NCT03913949
recruitingphase_2

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

NCT05147467
recruitingphase_1

A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

NCT06182969
recruitingphase_2

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

NCT04496349
recruitingphase_1

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

NCT04494503
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03913949Phase 1

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Active Not Recruiting
NCT05147467Phase 2

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Recruiting
NCT06182969Phase 1

A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

Recruiting
NCT04496349Phase 2

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

Recruiting
NCT04494503Phase 1

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Recruiting
NCT05701306Phase 1

APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

Recruiting
NCT04946864Phase 1

A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Suspended
NCT03537482Early Phase 1

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

Recruiting
NCT04674514Phase 1

APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9